Plasma-derived product labeling claims
FDA's Transmissible Spongiform Encephalopathies Advisory Committee will discuss labeling claims for TSE clearance studies for plasma-derived products on Oct. 14. Presumptive transfusion transmissions of variant Creutzfeldt-Jakob Disease and FDA recommended safeguards will also be addressed. The meeting will be held at the Hilton in Silver Spring, Md. beginning at 8 a.m. [To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.